ANDA 203187, held by Mylan. Lansoprazole.
As of Nov 21, 2026, ANDA 203187 (Lansoprazole), held by Mylan, was first approved by FDA on Jun 1, 2016, with 1 approved supplement and 0 published complete response letters.
Use treats frequent heartburn (occurs 2 or more days a week) not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 1, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lansoprazole15MG · capsule, delayed rel pellets;oral | Lansoprazole | Discontinued |
| Nov 24, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 1, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters